GlassScriptPhysician profile
Olendruff L Johnson
NPI 1730186669
$3,293.35
in general payments reported to CMS, 2019-2025
22 companies · $904 in 2025
The $904 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $637 · 2020: $157 · 2023: $670 · 2024: $926 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,406 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,405.81 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,034.09 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $776.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $302.45 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $215.73 | 2019-2025 | |
| Astellas Pharma US INC | $136.50 | 2023-2024 | Veozah, Myrbetriq |
| Inspire Medical Systems, INC. | $115.90 | 2023-2025 | Inspire |
| Amgen INC. | $115.23 | 2020-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $105.55 | 2020-2023 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $78.19 | 2019-2020 | |
| Exact Sciences Corporation | $66.39 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $53.42 | 2019-2025 | |
| Dexcom, INC. | $46.94 | 2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.86 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $45.54 | 2025 | Rexulti |
| Nevro Corp. | $30.65 | 2023 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $23.68 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbott Laboratories | $22.61 | 2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $19.05 | 2023 | |
| Arbor Pharmaceuticals, INC. | $17.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.82 | 2019 | |
| Allergan, INC. | $12.34 | 2019 | |
| Merck Sharp & Dohme LLC | $11.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olendruff Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.